Cargando…
Repurposing metformin for the treatment of gastrointestinal cancer
Diabetes mellitus type 2 and cancer share many risk factors. The pleiotropic insulin-dependent and insulin-independent effects of metformin might inhibit pathways that are frequently amplified in neoplastic tissue. Particularly, modulation of inflammation, metabolism, and cell cycle arrest are poten...
Autores principales: | Cunha Júnior, Ademar Dantas, Bragagnoli, Arinilda Campos, Costa, Felipe Osório, Carvalheira, José Barreto Campello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108031/ https://www.ncbi.nlm.nih.gov/pubmed/34007128 http://dx.doi.org/10.3748/wjg.v27.i17.1883 |
Ejemplares similares
-
Metformin and blood cancers
por: Cunha Júnior, Ademar Dantas, et al.
Publicado: (2018) -
Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?
por: da Cunha Júnior, Ademar Dantas, et al.
Publicado: (2021) -
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
por: Bragagnoli, Arinilda Campos, et al.
Publicado: (2021) -
Metformin for the treatment of breast cancer: protocol for a scoping review of randomised clinical trials
por: Araujo, Carolina Fumico Massuda, et al.
Publicado: (2021) -
Myosteatosis Differentially Affects the Prognosis of Non-Metastatic Colon and Rectal Cancer Patients: An Exploratory Study
por: Pozzuto, Lara, et al.
Publicado: (2021)